Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.52 |
| ▸ | CTSL | P07711 | 11/20 | 0.48 |
| ▸ | CTSB | P07858 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18541924 | 0.93 | CTSS (0.50) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL16449965 | 0.86 | CTSS (0.52) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL15837113 | 0.85 | CTSS (0.51) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL16449982 | 0.84 | MEN1 (0.52) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL15686296 | 0.83 | CTSS (0.54) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL16449984 | 0.83 | CTSS (0.49) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL18541946 | 0.83 | CTSS (0.49) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL15837157 | 0.82 | MEN1 (0.55) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL17228796 | 0.81 | CTSS (0.47) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL1150695 | 0.80 | CTSS (0.58) | CTSSCTSLCTSBCTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037580-A1 | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180022751-A1 | N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20170050961-A1 | IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-23 | — | — | US | disclosed |
| WO-2015165933-A2 | 6-SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022751-A1 | N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | GUCY1A2, GUCY1B2, GUCY1A1 | CTSS 3852/4885CTSL 3549/4885CTSB 3869/4885 |
| US-20180037580-A1 | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof | PC, PNPO, AADAC | CTSS 2525/4885CTSL 1942/4885CTSB 2405/4885 |
| US-20170050961-A1 | IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | GUCY1A2, GUCY1A1, GUCY1B2 | CTSS 3833/4885CTSL 3939/4885CTSB 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.